Quarterly report [Sections 13 or 15(d)]

Debt - Additional Information (Details)

v3.25.1
Debt - Additional Information (Details)
3 Months Ended 48 Months Ended
Nov. 18, 2025
USD ($)
Jan. 31, 2025
USD ($)
Oct. 28, 2024
Sep. 08, 2020
USD ($)
Debtinstrument
Jan. 21, 2020
USD ($)
Debtinstrument
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Jan. 31, 2025
USD ($)
shares
Apr. 27, 2018
USD ($)
$ / shares
shares
Nov. 18, 2015
USD ($)
Debt Instrument [Line Items]                    
Accretion of debt discounts and deferred financing costs           $ 194,000 $ 569,000      
Aggregate principal amount of exchangeable notes               $ 40,691,000    
Accrued and unpaid interest               $ 3,071,000    
Issuance of ordinary shares on conversion of exchangeable notes (in shares) | shares               3,760,155    
Aggregate principal amount               $ 40,691,000    
Pfizer License Agreement                    
Debt Instrument [Line Items]                    
Regulatory milestone payments upon approval of product $ 20,000,000                 $ 20,000,000
Regulatory and sales milestone deferred payment annual rate 8.00%                  
Regulatory and sales milestone deferred payment period     2 years              
Exchangeable Notes                    
Debt Instrument [Line Items]                    
Aggregate principal amount of exchangeable notes   $ 11,117,000           40,691,000    
Accrued and unpaid interest               3,071,000    
Aggregate principal amount   11,117,000           40,691,000    
Accrued interest   $ 3,628,000           3,628,000    
Exchangeable Notes | Private Placement                    
Debt Instrument [Line Items]                    
Aggregate principal amount of exchangeable notes               40,691,000    
Aggregate principal amount               $ 40,691,000    
Promissory Note                    
Debt Instrument [Line Items]                    
Interest expense           $ 404,000        
Loan and Security Agreement | Silicon Valley Bank (SVB)                    
Debt Instrument [Line Items]                    
Loan and security agreement entered date           Apr. 27, 2018        
Funded amount under agreement                 $ 15,000,000  
Maximum amount available under agreement                 $ 30,000,000  
Silicon Valley Bank and Life Sciences Fund II LLC | Ordinary Shares                    
Debt Instrument [Line Items]                    
Number of warrants to purchase ordinary shares | shares                 1,326  
Silicon Valley Bank and Life Sciences Fund II LLC | Series B Convertible Preferred Shares                    
Debt Instrument [Line Items]                    
Number of warrants to purchase ordinary shares | shares                 19,890  
Warrants to purchase preferred shares, exercise price | $ / shares                 $ 282.75  
2025 Exchangeable Notes                    
Debt Instrument [Line Items]                    
Interest expense           $ 88,000 181,000      
Accretion of debt discounts and deferred financing costs           $ 194,000 $ 569,000      
2025 Exchangeable Notes | Private Placement                    
Debt Instrument [Line Items]                    
Aggregate principal amount         $ 51,588,000          
Debt instrument price per unit         $ 1,000          
2025 Exchangeable Notes | Private Placement and Rights Offering                    
Debt Instrument [Line Items]                    
Aggregate principal amount       $ 51,800,000            
Debt instrument interest rate         6.50%          
2025 Exchangeable Notes | Rights Offering                    
Debt Instrument [Line Items]                    
Aggregate principal amount       220,000            
2020 Rights Offering | Private Placement                    
Debt Instrument [Line Items]                    
Debt instrument price per unit       1,000            
2020 Rights Offering | Rights Offering                    
Debt Instrument [Line Items]                    
Aggregate principal amount       $ 220,000            
RLNs | Private Placement                    
Debt Instrument [Line Items]                    
Aggregate principal amount         $ 103,000          
Number of debt instruments within each notes | Debtinstrument       50 50          
RLNs | Private Placement and Rights Offering                    
Debt Instrument [Line Items]                    
Aggregate principal amount       $ 500 $ 100,000          
RLNs | Rights Offering                    
Debt Instrument [Line Items]                    
Aggregate principal amount       440            
Securities | Private Placement                    
Debt Instrument [Line Items]                    
Debt instrument price per unit       $ 1,000 $ 1,000